Zogenix Reports Positive Results from Phase III Trial of Rare Childhood Epilepsy Study
Related Biotechnology, Pharmaceutical and Healthcare News
- Stock Alert: Zogenix (ZGNX) Plunges 29%
- Alector reports positive results from Phase I/Ib dementia study
- 2019 Childhood Epilepsy Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Published by VPA Research] Prices from USD $1799
- 2019 Childhood Epilepsy Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Report Updated: 24042019] Prices from USD $1583
- 2019 Childhood Epilepsy Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Report Updated: 24042019] Prices from USD $1799
Emeryville, California-based Zogenix announced positive topline data from its Phase III trial of Fintepla (fenfluramine) in Lennox-Gastaut Syndrome (LGS).
Original Article: Zogenix Reports Positive Results from Phase III Trial of Rare Childhood Epilepsy Study
NEXT ARTICLE
More From BioPortfolio on "Zogenix Reports Positive Results from Phase III Trial of Rare Childhood Epilepsy Study"